The Cancer Research Institute (CRI)–Chordoma Foundation Impact Grant 2027 supports translational research aimed at developing more effective immunotherapies for chordoma, a rare cancer affecting bones of the skull base and spine.
The joint program focuses on research that connects laboratory and clinical discovery and has a clear pathway toward improving outcomes for chordoma patients through new therapies, biomarkers, response prediction, or understanding mechanisms of treatment resistance.
Eligibility Criteria
- Applicants must hold a tenure-track assistant professor position or higher by award activation.
- Applicants who do not yet hold the position may provide institutional documentation confirming that they will do so by activation.
- There are no citizenship restrictions.
- Researchers at eligible institutions in the United States or internationally may apply.
- For-profit institutions are not eligible.
- Research must have direct clinical relevance to chordoma and cancer immunology.
- Projects should bridge laboratory and clinical discovery.
Funding Details
- Funding: $300,000
- Duration: 2 years
- Indirect costs of up to 10% are provided in addition to the award.
Deadline
- LOI deadline: December 1, 2026
- Applicants notified about full proposals: by the end of January 2027
- Invited full proposal: March 15, 2027
- Earliest award activation: July 1, 2027
- Applications close at 11:59 PM ET.
Further Information
- LOIs are submitted electronically through the CRI application system.
- Supporting documents include a CV, bibliography, current research description, and research concept.
- Official CRI Impact Grant